Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer

Maria Carmela Annunziata, Maria Ferrillo, Eleonora Cinelli, Luigia Panariello, Danilo Rocco, Gabriella Fabbrocini, Maria Carmela Annunziata, Maria Ferrillo, Eleonora Cinelli, Luigia Panariello, Danilo Rocco, Gabriella Fabbrocini

Abstract

Background: Tyrosine kinase inhibitors (TKIs) have been introduced for the treatment of lung cancer, improving progression-free survival, objective response rate, and quality of life. However, TKIs can lead to cutaneous toxicities, including papulopustular rash, xerosis, paronychia with/without pyogenic granulomas, scalp disorders, facial hair and/or eyelash growth.

Aim: In this study, we describe retrospectively all cases of mucocutaneous side effects in patients with lung cancer under TKIs referring to our outpatient for the skin care of oncological patients.

Methods: We included patients referring from January 2016 to January 2018 affected by lung cancer and under TKIs. We collected data about the clinical exam, clinical photography, dermoscopy, histology and direct microscopic examination for each patient and we performed retrospectively descriptive analyses to assess whether a specific TKIs is linked significantly to particular cutaneous toxicity.

Results: The majority of skin toxicities were due to afatinib, and the most common skin reaction was rash. We selected 60 patients with skin reactions, treated by TKIs for lung cancer. The majority of skin toxicities were due to afatinib (47/102 adverse reactions) and erlotinib (39/102). The most common skin reaction was rash (63% of patients), followed by xerosis (30%) and granulomas (30%). There was no significant relationship between a specific type of cutaneous reaction and specific EGFRi except for granulomas, developed more frequently in patients under afatinib (p < 0.05).

Conclusion: Most of our patients (63%) developed a cutaneous rash under TKIs. Most commonly afatinib was the drug involved, although it wasn't the most used EGFRi. Moreover, we noticed a significant correlation between afatinib therapy and appearance of granulomas.

Keywords: Anti-EGFR; Granuloma; Lung cancer; Rash; Skin toxicity.

Figures

Figure 1
Figure 1
Papulo-pustular rash under EGFRi in its typical localization (trunk and head)

References

    1. Data by World Health Organization.
    1. Zhang H. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionise the therapy of lung cancer. Drug Des Devel Ther. 2016;10:3867–3872. PMid:27920501 PMCid:PMC5125803.
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. PMid:19692680.
    1. Pastore S, Lulli D, Girolomoni G. Epidermal growth factor receptor signalling in keratinocyte biology:implications for skin toxicityof tyrosine kinase inhibitors. Arch Toxicol. 2014;88(6):1189–203. PMid:24770552.
    1. Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, et al. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitorsin the UK. Drugs. 2015;75(12):1335–48. PMid:26187773 PMCid:PMC4532717.
    1. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011;18(3):126–38. PMid:21655159 PMCid:PMC3108866.
    1. Nanba D, Toki F, Barrandon Y, Higashiyama S. Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation. J Dermatol Sci. 2013;72(2):81–6. PMid:23819985.
    1. Aw DC, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol. 2018;14(1):23–31. PMid:28464435.
    1. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500. .
    1. Arriola E, Reguart N, Artal A, Cobo M, García-Campelo R, Esteban E, et al. Management of the adverse events of afatinib:a consensus of the recommendations of the Spanish expert panel. Future Oncol. 2015;11(2):267–77. PMid:25236437.
    1. Schiefer M, Hendriks LEL, Dinh T, Lalji U, Dingemans AC. Current perspective:Osimertinib-induced QT prolongation:new drugs with new side-effects needcareful patient monitoring. Eur J Cancer. 2018;91:92–98. PMid:29413968.
    1. Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc. 2017;116(6):413–423. PMid:28351555.
    1. Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther. 2013;26(2):135–48. PMid:23551370.
    1. Pugliese SB, Neal JW, Kwong BY. Management of Dermatologic Complications of Lung Cancer Therapies. Curr Treat Options Oncol. 2015;16(10):50. PMid:26338208.
    1. Overbeck TR, Griesinger F. Two cases of psoriasis responding to erlotinib:time to revisiting inhibition of epidermal growthfactor receptor in psoriasis therapy? Dermatology. 2012;225(2):179–82. PMid:23095682.
    1. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol. 2004;84(4):308–9. PMid:15339078.
    1. Melosky B, Hirsh V. Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapieswith EGFR-TKIs. Front Oncol. 2014;4:238. PMid:25279350 PMCid:PMC4165207.
    1. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003;42(4):345–6. PMid:12899508.
    1. Razis E, Karina M, Karanastassi S, Fountzilas G. Three case reports of hand-foot syndrome with gefitinib. Cancer Invest. 2006;24(5):514–6. PMid:16939960.
    1. Zheng Y, Fang W, Xu N. Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib:A case report and review of the literature. Oncol Lett. 2012;4(6):1341–1343. PMid:23205134 PMCid:PMC3506748.
    1. Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents:A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(5):902–910. PMid:28918974 PMCid:PMC5657394.
    1. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–8. PMid:26826719 PMCid:PMC48↥1.
    1. Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4):e1004969. PMid:27308503 PMCid:PMC4905346.
    1. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining? J Clin Oncol. 2005;23(22):5235–46. PMid:16051966.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel